355 related articles for article (PubMed ID: 34111562)
1. Intranasal infusion of GD3 and GM1 gangliosides downregulates alpha-synuclein and controls tyrosine hydroxylase gene in a PD model mouse.
Itokazu Y; Fuchigami T; Morgan JC; Yu RK
Mol Ther; 2021 Oct; 29(10):3059-3071. PubMed ID: 34111562
[TBL] [Abstract][Full Text] [Related]
2. Restoration of Adult Neurogenesis by Intranasal Administration of Gangliosides GD3 and GM1 in The Olfactory Bulb of A53T Alpha-Synuclein-Expressing Parkinson's-Disease Model Mice.
Fuchigami T; Itokazu Y; Morgan JC; Yu RK
Mol Neurobiol; 2023 Jun; 60(6):3329-3344. PubMed ID: 36849668
[TBL] [Abstract][Full Text] [Related]
3. Ganglioside Microdomains on Cellular and Intracellular Membranes Regulate Neuronal Cell Fate Determination.
Itokazu Y; Yu RK
Adv Neurobiol; 2023; 29():281-304. PubMed ID: 36255679
[TBL] [Abstract][Full Text] [Related]
4. GM1 Ganglioside Modifies α-Synuclein Toxicity and is Neuroprotective in a Rat α-Synuclein Model of Parkinson's Disease.
Schneider JS; Aras R; Williams CK; Koprich JB; Brotchie JM; Singh V
Sci Rep; 2019 Jun; 9(1):8362. PubMed ID: 31182727
[TBL] [Abstract][Full Text] [Related]
5. GM1 ganglioside modifies microglial and neuroinflammatory responses to α-synuclein in the rat AAV-A53T α-synuclein model of Parkinson's disease.
Schneider JS; Singh G; Williams CK; Singh V
Mol Cell Neurosci; 2022 May; 120():103729. PubMed ID: 35447351
[TBL] [Abstract][Full Text] [Related]
6. GM1 ganglioside restores dopaminergic neurochemical and morphological markers in aged rats.
Goettl VM; Wemlinger TA; Duchemin AM; Neff NH; Hadjiconstantinou M
Neuroscience; 1999; 92(3):991-1000. PubMed ID: 10426539
[TBL] [Abstract][Full Text] [Related]
7. Alpha-synuclein aggregation alters tyrosine hydroxylase phosphorylation and immunoreactivity: lessons from viral transduction of knockout mice.
Alerte TN; Akinfolarin AA; Friedrich EE; Mader SA; Hong CS; Perez RG
Neurosci Lett; 2008 Apr; 435(1):24-9. PubMed ID: 18314273
[TBL] [Abstract][Full Text] [Related]
8. Alpha-Synuclein and GM1 Ganglioside Co-Localize in Neuronal Cytosol Leading to Inverse Interaction-Relevance to Parkinson's Disease.
Kumar R; Chowdhury S; Ledeen R
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542297
[TBL] [Abstract][Full Text] [Related]
9. Gangliosides, α-Synuclein, and Parkinson's Disease.
Ledeen RW; Wu G
Prog Mol Biol Transl Sci; 2018; 156():435-454. PubMed ID: 29747823
[TBL] [Abstract][Full Text] [Related]
10. Chronic GM1 ganglioside treatment reduces dopamine cell body degeneration in the substantia nigra after unilateral hemitransection in rat.
Toffano G; Savoini GE; Moroni F; Lombardi G; Calzà L; Agnati LF
Brain Res; 1984 Apr; 296(2):233-9. PubMed ID: 6142756
[TBL] [Abstract][Full Text] [Related]
11. Autophagy-dependent removal of α-synuclein: a novel mechanism of GM1 ganglioside neuroprotection against Parkinson's disease.
Guo YL; Duan WJ; Lu DH; Ma XH; Li XX; Li Z; Bi W; Kurihara H; Liu HZ; Li YF; He RR
Acta Pharmacol Sin; 2021 Apr; 42(4):518-528. PubMed ID: 32724177
[TBL] [Abstract][Full Text] [Related]
12. Depopulation of dense α-synuclein aggregates is associated with rescue of dopamine neuron dysfunction and death in a new Parkinson's disease model.
Wegrzynowicz M; Bar-On D; Calo' L; Anichtchik O; Iovino M; Xia J; Ryazanov S; Leonov A; Giese A; Dalley JW; Griesinger C; Ashery U; Spillantini MG
Acta Neuropathol; 2019 Oct; 138(4):575-595. PubMed ID: 31165254
[TBL] [Abstract][Full Text] [Related]
13. Deficiency of ganglioside GM1 correlates with Parkinson's disease in mice and humans.
Wu G; Lu ZH; Kulkarni N; Ledeen RW
J Neurosci Res; 2012 Oct; 90(10):1997-2008. PubMed ID: 22714832
[TBL] [Abstract][Full Text] [Related]
14. Intraventricular Sialidase Administration Enhances GM1 Ganglioside Expression and Is Partially Neuroprotective in a Mouse Model of Parkinson's Disease.
Schneider JS; Seyfried TN; Choi HS; Kidd SK
PLoS One; 2015; 10(12):e0143351. PubMed ID: 26629687
[TBL] [Abstract][Full Text] [Related]
15. AAV1/2-induced overexpression of A53T-α-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson's disease.
Ip CW; Klaus LC; Karikari AA; Visanji NP; Brotchie JM; Lang AE; Volkmann J; Koprich JB
Acta Neuropathol Commun; 2017 Feb; 5(1):11. PubMed ID: 28143577
[TBL] [Abstract][Full Text] [Related]
16. Gangliosides in neural stem cell fate determination and nerve cell specification--preparation and administration.
Itokazu Y; Ariga T; Fuchigami T; Li D
bioRxiv; 2024 Jun; ():. PubMed ID: 38915682
[TBL] [Abstract][Full Text] [Related]
17. Generation of a alpha-synuclein-based rat model of Parkinson's disease.
Recchia A; Rota D; Debetto P; Peroni D; Guidolin D; Negro A; Skaper SD; Giusti P
Neurobiol Dis; 2008 Apr; 30(1):8-18. PubMed ID: 18313315
[TBL] [Abstract][Full Text] [Related]
18. Parkinson's disease recovery by GM1 oligosaccharide treatment in the B4galnt1
Chiricozzi E; Mauri L; Lunghi G; Di Biase E; Fazzari M; Maggioni M; Valsecchi M; Prioni S; Loberto N; Pomè DY; Ciampa MG; Fato P; Verlengia G; Cattaneo S; Assini R; Wu G; Alselehdar S; Ledeen RW; Sonnino S
Sci Rep; 2019 Dec; 9(1):19330. PubMed ID: 31852959
[TBL] [Abstract][Full Text] [Related]
19. Chronic intranasal deferoxamine ameliorates motor defects and pathology in the α-synuclein rAAV Parkinson's model.
Febbraro F; Andersen KJ; Sanchez-Guajardo V; Tentillier N; Romero-Ramos M
Exp Neurol; 2013 Sep; 247():45-58. PubMed ID: 23531432
[TBL] [Abstract][Full Text] [Related]
20. Nurr1 in Parkinson's disease and related disorders.
Chu Y; Le W; Kompoliti K; Jankovic J; Mufson EJ; Kordower JH
J Comp Neurol; 2006 Jan; 494(3):495-514. PubMed ID: 16320253
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
